Delighted to share our latest work on #longCOVID - sex differences in symptoms and immune signatures. Led by @SilvaJ_C @taka_takehiro @wood_jamie_1 et al. with @LeyingGuan & @PutrinoLab. We find a striking inverse correlation btw testosterone levels and symptom burden👇🏼 (1/)
This work leverages data from our recent Mount Sinai-Yale long COVID "MY-LC" study with the @PutrinoLab. This time, we asked the question, "Are there differences in symptoms and immune signatures of ♀️ vs. ♂️ with LC"? (2/)
While some symptoms were equally frequent in females and males, many were more frequent in females (e.g., swelling, headaches, muscle pain, cramps) than males. The top distinguishing symptoms of LC status by sex were hair loss in females and sexual dysfunction in males. (3/)
What organ-specific symptoms correlate with one another in females vs. males? In females (left), temperature-related symptoms and musculoskeletal symptoms were strongly associated with other symptoms. In males (right), ear nose and throat (ENT) symptoms were most associated with other symptoms. (4/)
What about immune signatures? Females with LC had increases in exhausted and cytokine-secreting T cells and antibodies against lytic antigens from herpesviruses, suggestive of recent reactivation. (5/)
In contrast, males with LC had elevated NK cells, reduced monocytes and plasmacytoid dendritic cells. They also had increases in TGF-beta, APRIL and IL-8, features not significantly different in females with LC. (6/)
Females with LC had significantly lower testosterone levels. Using logistic regression, @SilvaJ_C found testosterone to be the top negative hormone predictor of LC status in females based on per unit odds ratio. Thus, in females, the lower the testosterone, the more likely to have LC. (7/)
In males, those with LC had lower levels of estradiol, and estradiol was found to be the top negative predictor hormone of LC status. (8/)
Next, @silvaJ_C took a different machine-learning approach. This time he divided the MY-LC cohort into training vs. testing sets. He took cellular profiles and plasma factors but excluded hormones within females and males separately and calculated sex-specific immune scores. (9/)
This strategy successfully predicted LC status in females (86% accuracy) and males (87% accuracy). Meaning that cellular and soluble immune features alone can distinguish those with LC in both sexes pretty accurately. (10/)
Using this modeling strategy, we found that female LC immune signatures were associated with higher symptom burden, organ involvement and dysautonomia in males with LC. Conversely, male LC immune signatures correlated with lower symptom burden, dysautonomia and neurocognitive symptoms in females with LC! Overall, male LC immune signatures meant less symptoms in LC. (11/)
So what is driving the male LC immune signatures? Testosterone! Regardless of sex, those with higher testosterone levels had higher male LC immune signatures. Those with lower testosterone had higher female LC immune signatures. (12/)
Finally, testosterone levels could significantly predict not just LC status but also symptom burden and organ system involvement in individuals with LC irrespective of sex. (13/)
To summarize, we find significant differences in symptoms and immune signatures in females vs. males with long COVID. (14/)
There is a fascinating backstory to this study I wish to share (with permission). In August of 2022, @tarazupancic DM me about a profound improvement in the long COVID symptoms of her child after receiving testosterone for gender-affirming care. I discussed this at our weekly long COVID lab science meeting. This is how it all started. So grateful to Tara for sharing this key insight with us 🙏🏼🙏🏼 (15/)
As always, this was a huge undertaking by many dedicated scientists and clinicians, and the amazing contributions of patients who donated their time, effort and blood samples. Incredible teamwork with the Mount Sinai team @PutrinoLab. Kudos to @SilvaJ_C, @taka_takehiro, @wood_jamie_1, @peowenlu, @S_Tabachnikova, @JeffGehlhausen, @KerrieGreene_ , @bornali_27, Valter Silva Monteiro, @carolilucas, @rahuldhodapkar, @marioph13, Kathy Kamath, @tianyangmao, Dayna Mccarthy, @RMedzhitov, @david_van_dijk, @hmkyale and @LeyingGuan!!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Published today! Victoria Bastos, @KerrieGreene_ et al found two distinct immunotypes of ME/CFS based on the cerebrospinal fluid analysis. Great collaboration with @MBVanElzakker @microbeminded2 and the Bragée clinic in Sweden. (1/) academic.oup.com/jimmunol/artic…
This is perfect timing as Victoria will present these data at the @polybioRF symposium today. (2/)
Based on cerebrospinal fluid cytokines, we identified two clusters of ME/CFS patients. Cluster 1 had elevated matrix metalloproteinases & many cytokines compared to cluster 2. Other than older age (Cluster 1), clinical presentation of these clusters was similar. (3/)
Published today📣
Our nasal booster in the "Prime & Spike" vaccine works without adjuvants (which are needed to induce adaptive immunity but also cause inflammation). @Kwon_Dongil @tianyangmao @BenIsraelow et al. asked how this is possible. (1/) nature.com/articles/s4159…
Prime & Spike is a vaccine strategy that leverages preexisting immunity primed by conventional vaccines to elicit mucosal IgA and T cell responses that prevent COVID infection and transmission in rodents. The nasal booster is simply the spike protein (2/) science.org/doi/10.1126/sc…
Our new study shows that the nasal spike protein booster converts lymph node memory B cells into IgA-secreting cells in the lung with the help of memory CD4 T cells. Ag-specific CD4 T cells replace all the necessary functions of adjuvants without nonspecific inflammation! (3/)
This prospective observational study led by @connorbgrady @bornali_27 @SilvaJ_C @hmkyale examined the impact of the primary COVID-19 vaccination on the symptoms and immune signatures of 16 people with #longCOVID. Here is what we found 👇🏼 (1/)
This study asked: Does COVID vaccination improve symptoms of long COVID? If so, is the improvement due to robust T and B cell responses leading to the clearance of the viral reservoir? If not, is there an immune feature that predicts worsening of LC? (2/)
The self-reported impact of vaccination was variable. Of the 16 long COVID patients, 10 felt better, 3 had no change, and 3 had worse health (1 hospitalized) 12 weeks after vaccination. Both physical and social effects of symptom burden appeared to decrease after vaccination. (3/)
Our preprint on post-vaccination syndrome is out. We studied immune signatures and examined spike protein in the blood of people who have developed chronic illnesses after COVID-19 vaccination. (1/) medrxiv.org/content/10.110…
Vaccines have saved countless lives and inspired me to become an immunologist. While generally safe, some people experience adverse effects, including Post-Vaccination Syndrome (PVS). Studying PVS is crucial for improving patient care and enhancing vaccine safety & acceptance. (2/) pubmed.ncbi.nlm.nih.gov/37986769/
Happy to share our latest work by @YYexin et al. on antibody-mediated control of endogenous retroviruses in mice. In the process, we found “natural antibodies” with broad reactivity against enveloped viruses. Here is how “panviral” antibodies work 🧵(1/)
Endogenous retroviruses (ERV) are remnants of genetic invaders that have integrated into our ancestors' genomes over millions of years. ERVs occupy ~8% of the human genome and are under constant host immune surveillance. (2/) nature.com/articles/nrg31… nature.com/articles/nrmic…
This work started over 7 years ago when @YYexin and @rebecca_treger began to examine why ERVs reactivate in certain mouse strains. Through many genetic crosses, we figured out that secreted IgM recruits complement to suppress infectious ERV from emerging. (3/)
This time, we developed a nasal booster vaccine for influenza viruses. In this preprint, @MiyuMoriyama et al. show that nasal boosters with unadjuvanted hemagglutinin protein induce sterilizing immunity in mice against flu. (1/) biorxiv.org/content/10.110…
This work builds on the Prime and Spike vaccine strategy by @tianyangmao @BenIsraelow et al. against COVID where mRNA vaccine followed by nasal booster with recombinant spike protein established local immunity, ⬇️ infection & transmission in rodents. (2/) science.org/doi/10.1126/sc…
For Prime and HA against flu, @MiyuMoriyama tested several different mRNA IM prime and nasal HA booster doses, followed by a homologous influenza virus challenge. Like Prime and Spike, no adjuvant is needed for the nasal booster due to preexisting immunity from Prime. (3/)